Clinical Trials Browser

Recurrence × Genitourinary × 30 days × Clear all

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT07197580 2026-04-01

LUTEON

Phase 3 Recruiting

40 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT07420517 2026-03-30

DutaBCa-1

Phase 2 Recruiting

95 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT02650401 2026-03-25

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 2 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05328505 2026-03-24

MIDAS-Prostate

Phase NA Recruiting

80 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms, Recurrence

NCT05037279 2026-03-20

EVER

Phase 3 Recruiting

540 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT05283330 2026-03-20

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Phase 1 Recruiting

48 enrolled

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Glioblastoma, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT06126172 2026-03-20

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions

Phase NA Active not recruiting

125 enrolled

Genitourinary

Prostatic Neoplasms, Recurrence

Clinical Trials

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

LUTEON

DutaBCa-1

STARTRK-NG

MIDAS-Prostate

EVER

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions